This is a proof-of-concept technical milestone with no near-term revenue or clinical catalyst. Monitor for future announcements regarding progression from simulation to actual quantum computing hardware execution, or any partnership agreements with the S&P 500 company whose quantum architecture was used.
Price Chart
Executive Summary
SciSparc announced via press release that its majority-owned subsidiary NeuroThera Labs' subsidiary CliniQuantum achieved a ~16.8x computational acceleration on a quantum-simulation platform using an NVIDIA T4 GPU versus CPU-only processing, analyzing ~7.3 billion gene triplets from a real clinical dataset. This is a technical benchmark milestone with no clinical validation or near-term revenue implications, and the filing contains no financial data or guidance.
Key Facts
- CliniQuantum's GPU-accelerated quantum-simulation platform achieved ~16.8-fold computational acceleration using a single machine with 64 cores and a single NVIDIA T4 GPU vs. CPU-only implementation.
- The benchmark analyzed 3,531 gene-expression features from 11 patients, generating ~7.33 billion possible three-gene combinations and identifying ~22.2 million correlated gene triplets.
- Analysis time reduced from ~8.4 hours (64 vCPUs) to ~0.5 hours (single NVIDIA T4 GPU).
- The benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using IBM Qiskit Aer GPU-based quantum simulation.
- The press release explicitly states the benchmark did not evaluate clinical validity, predictive value, or potential utility of any identified gene combinations.
- No financial data, revenue, earnings, guidance, or material agreements were disclosed in this filing.
Financial Impact
No financial impact disclosed; this is a technical benchmark with no revenue or cost figures.
Risk Factors
- No clinical or commercial validation has been established for the identified gene combinations.
- The benchmark is purely computational and does not demonstrate therapeutic or diagnostic utility.
- SciSparc/NeuroThera remain pre-revenue clinical-stage companies with no guarantee of successful commercialization.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-107436 |
| Document: ea030793702ex99-1.htm | 0001213900-26-107436 |
| Document: 0001213900-26-107436-index-headers.html | 0001213900-26-107436 |
| Document: 0001213900-26-107436-index.html | 0001213900-26-107436 |
| Document: 0001213900-26-107436.txt | 0001213900-26-107436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.29 | awaiting T+5 | — | $0.8500 (+34.08%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $0.8500 (−22.02%) |
Oct 22, 2026 5d ago | Press Release | $1.20 | awaiting T+5 | — | $0.8500 (−29.17%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $0.8500 (+57.50%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 7, 2026 20d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $0.8500 (−81.68%) |
Sep 30, 2026 27d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $0.8500 (+81.32%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $0.8500 (−84.23%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $0.8500 (−83.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers